Biochemical and laboratory findings of HCV+, t(14;18)+ CLD patients followed up after the end of therapy
No. . | ALT × ULN level . | Serum HCV RNA titer . | BL HCV RNA . | t(14;18) . |
|---|---|---|---|---|
| 1 | 2.42 | 3.7 × 105 | + | + |
| 2 | 1.87 | 1.0 × 106 | + | + |
| 3 | 2.95 | 2.0 × 106 | + | + |
| 4 | 1.92 | +ND | + | + |
| 5 | 0.35 | - | - | - |
| 6 | 1.62 | +ND | + | - |
| 8 | 0.55 | +ND | + | + |
| 10 | 2.20 | 1.0 × 106 | + | + |
| 12 | 5.67 | 1.0 × 105 | + | - |
| 13 | 1.00 | 5.0 × 105 | - | - |
| 14 | 3.95 | 2.6 × 105 | + | + |
| 15 | 0.97 | 1.0 × 106 | + | + |
| 16 | 2.27 | 1.0 × 106 | + | + |
| 17 | 0.95 | +ND | + | - |
| 19 | 2.15 | 8.5 × 105 | + | - |
| 25 | 0.60 | 1.9 × 105 | - | - |
| 30 | 4.07 | + | ND | - |
No. . | ALT × ULN level . | Serum HCV RNA titer . | BL HCV RNA . | t(14;18) . |
|---|---|---|---|---|
| 1 | 2.42 | 3.7 × 105 | + | + |
| 2 | 1.87 | 1.0 × 106 | + | + |
| 3 | 2.95 | 2.0 × 106 | + | + |
| 4 | 1.92 | +ND | + | + |
| 5 | 0.35 | - | - | - |
| 6 | 1.62 | +ND | + | - |
| 8 | 0.55 | +ND | + | + |
| 10 | 2.20 | 1.0 × 106 | + | + |
| 12 | 5.67 | 1.0 × 105 | + | - |
| 13 | 1.00 | 5.0 × 105 | - | - |
| 14 | 3.95 | 2.6 × 105 | + | + |
| 15 | 0.97 | 1.0 × 106 | + | + |
| 16 | 2.27 | 1.0 × 106 | + | + |
| 17 | 0.95 | +ND | + | - |
| 19 | 2.15 | 8.5 × 105 | + | - |
| 25 | 0.60 | 1.9 × 105 | - | - |
| 30 | 4.07 | + | ND | - |
CLD indicates chronic liver disease; ALT × ULN, alanine aminotransferase as multiple of upper limit of normal values; BL, peripheral B lymphocyte; and ND, not done.